NCBI » Bookshelf » Molecular Imaging and Contrast Agent Database » PET » 64Cu » 64Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-polyethylene-glycol-single-walled nanotube-c(RGDyK)
 
micad
Molecular Imaging and Contrast Agent Database
LeungKam
ChopraArvind
National Center for Biotechnology Information (NCBI)
imaging

MICAD Summary

Download a summary of all MICAD entries as a comma-separated-values file containing the fields:

64Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-polyethylene-glycol-single-walled nanotube-c(RGDyK)
[64Cu-DOTA-SWNT-PEG-c(RGDyK)]

Kam Leung, PhD
National Center for Biotechnology Information, NLM, NIH, Email:
21102008RGDyK-SWNT-64Cu
Created: October 6, 2008.
Last Update: October 21, 2008.
Chemical name:64Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-polyethylene-glycol-single-walled nanotube-c(RGDyK)
Abbreviated name:64Cu-DOTA-SWNT-PEG-c(RGDyK)
Synonym:
Agent category:Peptide
Target:Integrin αvβ3
Target category:Receptor
Method of detection:PET
Source of signal\contrast:64Cu
Activation:No
Studies:
  • In vitro

  • Rodents

Click on protein, nucleotide (RefSeq), and gene for more information about integrin αvβ3.

Background

[PubMed]

Optical fluorescence imaging is increasingly used to visualize biological functions of specific targets (1, 2). However, the intrinsic fluorescence of biomolecules poses a problem when fluorophores that absorb visible light (350–700 nm) are used. Near-infrared (NIR) fluorescence (700–1,000 nm) detection avoids the background fluorescence interference of natural biomolecules, providing a high contrast between target and background tissues. NIR fluorophores have wider dynamic range and minimal background as a result of reduced scattering compared with visible fluorescence detection. They also have high sensitivity, resulting from low infrared background, and high extinction coefficients, which provide high quantum yields. The NIR region is also compatible with solid-state optical components, such as diode lasers and silicon detectors. NIR fluorescence imaging is becoming a non-invasive alternative to radionuclide imaging in small animals.

Carbon nanotubes are made of carbon fullerene carbon units, which respond to local dielectric changes without photobleaching (3, 4). They can be tuned in a range of wavelengths for NIR absorption, thus providing broad excitation profiles and high absorption coefficients. They can be coated and capped with hydrophilic materials for additional conjugation with biomolecules, such as peptides, antibodies, nucleic acids, and small organic compounds for in vitro and in vivo studies (5). Single-walled carbon nanotubes (SWNTs) have a diameter of 1–5 nm and a length of 200–1,000 nm, and they have been shown to be non-toxic to cells in vitro (6). However, there have been limited in vivo studies of SWNT toxicological and pharmacological profiles in small animals.

Integrins are a family of heterodimeric glycoproteins on cell surfaces that mediate diverse biological events involving cell–cell and cell–matrix interactions (7). Integrins consist of an α and a β subunit and are important for cell adhesion and signal transduction. The αvβ3 integrin is the most prominent receptor affecting tumor growth, tumor invasiveness, metastasis, tumor-induced angiogenesis, inflammation, osteoporosis, and rheumatoid arthritis (8-13). Expression of the αvβ3 integrin is strong in tumor cells and activated endothelial cells, whereas expression is weak in resting endothelial cells and most normal tissues. Antagonists of αvβ3 are being studied as antitumor and antiangiogenic agents and the agonists of αvβ3 are being studied as angiogenic agents for coronary angiogenesis (12, 14, 15). A peptide sequence consisting of Arg-Gly-Asp (RGD) has been identified as a recognition motif used by extracellular matrix proteins (vitronectin, fibrinogen, laminin, and collagen) to bind to a variety of integrins, including αvβ3. Various ligands have been introduced for imaging of tumors and tumor angiogenesis (16). Liu et al. (17) conjugated 64Cu-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (64Cu-DOTA) and c(RGDyK) to phospholipid-polyethylene-glycol (PL-PEG)–coated SWNTs (64Cu-DOTA-SWNT-PEG-c(RGDyK)) for imaging αvβ3 integrin expression in tumors and their vasculatures.

Synthesis

[PubMed]

Liu et al. (17) performed sonication of SWNTs in a solution of PL-PEG4500-NH2 for 1 h to obtain SWNT-PEG4500-NH2, which exhibits a molar extension coefficient of 7.9 × 106 M-1cm-1 at 808 nm absorbance. The average length of the SWNTs was ~200 nm. SWNT-PEG4500-NH2 nanotubes were incubated with DOTA-N-hydroxysulfonosuccinimide (SNHS) for 4 h (pH 7.4) to form SWNT-PEG4500-DOTA; there were ~62 DOTA molecules per SWNT. To prepare conjugates with both DOTA and RGD, DOTA-SNHS and sulphosuccinimidyl 4-N-maleimidomethyl cyclohexane-1-carboxylate were mixed at 1:5 molar ratios and incubated in SWNT-PEG-NH2 solutions for 2 h (pH 7.4). The resulted SWNTs were reacted overnight with 0.2 mM thiolated c(RGDyK) in the presence of 10 mM Tris(2-carboxyethyl) phosphine hydrochloride (pH 7.4), yielding DOTA-SWNT-PEG5400-RGD with both RGD and DOTA on the SWNTs. There were 36.2 c(RGDyK) molecules per SWNT with a c(RGDyK)/DOTA ratio of 0.59. DOTA-SWNT-PEG2000-RGD was prepared similarly with the use of PL-PEG2000-NH2. There were 47.4 c(RGDyK) molecules per SWNT with a c(RGDyK)/DOTA ratio of 0.71. 64CuCl2 (74 MBq (2 mCi)) was added to 150 nM SWNT conjugates in 0.1 M NaOAc solution (pH 6.5). The reaction mixture was incubated for 1 h at 40°C. The radiolabeled yield was 60–80% with a specific activity of ~370 MBq/µmol (~10 mCi/µmol). 64Cu-SWNT conjugates in mouse serum remained intact at 37°C after 24 h incubation.

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

Liu et al. (17) performed in vitro inhibition studies of DOTA-SWNT-PEG5400-RGD and DOTA-SWNT-PEG2000-RGD in cultured U87MG human glioblastoma cells with 125I-echistatin. The 50% inhibition concentration values for DOTA-SWNT-PEG5400-RGD and DOTA-SWNT-PEG2000-RGD were 11.1 and 4.1 nM, respectively.

Animal Studies

Rodents

[PubMed]

Liu et al. (17) performed biodistribution studies of 64Cu-DOTA-SWNT-PEG5400-RGD and 64Cu-DOTA-SWNT-PEG2000-RGD in nude mice (n = 3 mice/group) bearing U87MG tumors after injection of 7.4–11.1 MBq (0.2–0.3 mCi) of the tracers. Tracer accumulation in the αvβ3-integrin-expressing U87MG tumor was higher for 64Cu-DOTA-SWNT-PEG5400-RGD (~13% injected dose (ID)/g) than 64Cu-DOTA-SWNT-PEG2000-RGD (~4% ID/g) at 24 h. The highest radioactive concentration was found in the liver with ~19% ID/g for 64Cu-DOTA-SWNT-PEG4500-RGD and ~28% ID/g for 64Cu-DOTA-SWNT-PEG2000-RGD. On the other hand, the spleen, kidney, and lung accumulated ~5% ID/g for both tracers. 64Cu-DOTA-SWNT-PEG5400 and 64Cu-DOTA-SWNT-PEG2000 exhibited biodistribution similar to their RGD conjugates with only 3–4% ID/g radioactivity in the tumor. 64Cu-DOTA-SWNT-PEG2000 (~35% ID/g) also exhibited a higher liver accumulation than 64Cu-DOTA-SWNT-PEG4500 (~19% ID/g). 64Cu-DOTA-SWNT-PEG5400 (~2 h) exhibited a longer blood half-life than 64Cu-DOTA-SWNT-PEG2000 (~0.5 h). Positron emission tomography imaging in nude mice bearing U87MG tumors with the 64Cu-DOTA-SWNT conjugates visualized the tumors at 0.5, 6, 18, and 24 h. 64Cu-DOTA-SWNT-PEG5400 and 64Cu-DOTA-SWNT-PEG2000 exhibited only 3–4% ID/g in the tumor, whereas 64Cu-DOTA-SWNT-PEG5400-RGD and 64Cu-DOTA-SWNT-PEG2000-RGD exhibited ~15% ID/g and ~5% ID/g at 24 h, respectively. Tumor accumulation was rapid and reached a plateau at 6 h. Tumor/muscle ratio was >15 for 64Cu-DOTA-SWNT-PEG5400-RGD. There was relatively low radioactivity elsewhere (except the liver) in the mice, confirming the biodistribution data. 64Cu-DOTA-SWNT-PEG2000 exhibited a higher liver accumulation than 64Cu-DOTA-SWNT-PEG4500 as shown in the biodistribution studies. Co-administration of c(RGDyK) with 64Cu-DOTA-SWNT-PEG5400-RGD inhibited tumor accumulation by ~75%. Low tumor accumulation (~3% ID/g) of 64Cu-DOTA-SWNT-PEG5400-RGD was observed in mice bearing HT-29 tumors (αvβ3-integrin negative). Raman spectroscopy analysis (SWNTs, G band, ~1,600 cm-1) of various tissues confirmed the co-localization of SWNTs and 64Cu.

Other Non-Primate Mammals

[PubMed]

No publication is currently available.

Non-Human Primates

[PubMed]

No publication is currently available.

Human Studies

[PubMed]

No publication is currently available.

NIH Support

R21 EB001785, R21 CA102123, P50 CA114747, R24 CA93862, U54 CA93862

References
1.
Ntziachristos V., Bremer C., Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol. 2003; 13(1): 195208. [PubMed]
2.
Achilefu S. Lighting up tumors with receptor-specific optical molecular probes. Technol Cancer Res Treat. 2004; 3(4): 393409. [PubMed]
3.
Hersam M.C. Progress towards monodisperse single-walled carbon nanotubes. Nat Nanotechnol. 2008; 3(7): 38794. [PubMed]
4.
Barone P.W., Baik S., Heller D.A., Strano M.S. Near-infrared optical sensors based on single-walled carbon nanotubes. Nat Mater. 2005; 4(1): 8692. [PubMed]
5.
Klumpp C., Kostarelos K., Prato M., Bianco A. Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta. 2006; 1758(3): 40412. [PubMed]
6.
Chin S.F., Baughman R.H., Dalton A.B., Dieckmann G.R., Draper R.K., Mikoryak C., Musselman I.H., Poenitzsch V.Z., Xie H., Pantano P. Amphiphilic helical peptide enhances the uptake of single-walled carbon nanotubes by living cells. Exp Biol Med (Maywood). 2007; 232(9): 123644. [PubMed]
7.
Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992; 69(1): 1125. [PubMed]
8.
Jin H., Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004; 90(3): 5615. [PubMed]
9.
Varner J.A., Cheresh D.A. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol. 1996: 6987. [PubMed]
10.
Wilder R.L. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases Ann Rheum Dis 2002. 61:Suppl 2ii969. [PubMed].
11.
Grzesik W.J. Integrins and bone--cell adhesion and beyond. Arch Immunol Ther Exp (Warsz). 1997; 45(4): 2715. [PubMed]
12.
Kumar C.C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003; 4(2): 12331. [PubMed]
13.
Ruegg C., Dormond O., Foletti A. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium. 2002; 9(3): 15160. [PubMed]
14.
Kerr J.S., Mousa S.A., Slee A.M. Alpha(v)beta(3) integrin in angiogenesis and restenosis. Drug News Perspect. 2001; 14(3): 14350. [PubMed]
15.
Mousa S.A. alphav Vitronectin receptors in vascular-mediated disorders. Med Res Rev. 2003; 23(2): 1909. [PubMed]
16.
Haubner R., Wester H.J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des. 2004; 10(13): 143955. [PubMed]
17.
Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., Chen X., Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007; 2(1): 4752. [PubMed]
Help ǀ Contact Bookshelf
Molecular Imaging and Contrast Agent Database
(navigation arrows) Go to previous chapter Go to next chapter Go to top of this page Go to bottom of this page Go to Table of Contents